Dr. med. Nikolaus Wagner
Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single institutional cohort study.
Wagner N, Knierim S, Luttermann F, Metzler G, Yazdi A, Bauer J, Gassenmaier M, Forschner A, Leiter U, Amaral T, Garbe C, Eigentler T, Forchhammer S, Flatz L. Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single institutional cohort study. J Am Acad Dermatol 2023
Dec 1, 2023Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single institutional cohort study.
Dec 1, 2023J Am Acad Dermatol 2023
Wagner Nikolaus, Knierim Sarah M, Luttermann Felix, Metzler Gisela, Yazdi Amir Sadegh, Bauer Jürgen, Gassenmaier Maximilian, Forschner Andrea, Leiter Ulrike, Amaral Teresa, Garbe Claus, Eigentler Thomas Kurt, Forchhammer Stephan, Flatz Lukas
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Wagner N, Lenders M, Kühl K, Reinhardt L, Fuchß M, Ring N, Stäger R, Zellweger C, Ebel C, Kimeswenger S, Oellinger A, Amaral T, Forschner A, Leiter U, Klumpp B, Hoetzenecker W, Terheyden P, Mangana J, Loquai C, Cozzio A, Garbe C, Meier F, Eigentler T, Flatz L. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy. Eur J Cancer 2023; 196:113425.
Nov 21, 2023Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Nov 21, 2023Eur J Cancer 2023; 196:113425
Wagner Nikolaus, Lenders Max M, Kühl Kathrin, Reinhardt Lydia, Fuchß Milena, Ring Natalie, Stäger Ramon, Zellweger Caroline, Ebel Chiara, Kimeswenger Susanne, Oellinger Angela, Amaral Teresa, Forschner Andrea, Leiter Ulrike, Klumpp Bernhard, Hoetzenecker Wolfram, Terheyden Patrick, Mangana Joanna, Loquai Carmen, Cozzio Antonio, Garbe Claus, Meier Friedegund, Eigentler Thomas Kurt, Flatz Lukas
Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.
Gaissler A, Bochem J, Spreuer J, Ottmann S, Martens A, Amaral T, Wagner N, Claassen M, Meier F, Terheyden P, Garbe C, Eigentler T, Weide B, Pawelec G, Wistuba-Hamprecht K. Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma. J Immunother Cancer 2023; 11
Jun 1, 2023Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.
Jun 1, 2023J Immunother Cancer 2023; 11
Gaissler Andrea, Bochem Jonas, Spreuer Janine, Ottmann Shannon, Martens Alexander, Amaral Teresa, Wagner Nikolaus, Claassen Manfred, Meier Friedegund, Terheyden Patrick, Garbe Claus, Eigentler Thomas Kurt, Weide Benjamin, Pawelec Graham, Wistuba-Hamprecht Kilian
Swiss Recommendations for Cutaneous Basal Cell Carcinoma.
Ramelyte E, Nägeli M, Hunger R, Merat R, Gaide O, Navarini A, Cozzio A, Wagner N, Maul L, Dummer R. Swiss Recommendations for Cutaneous Basal Cell Carcinoma. Dermatology 2022; 239:1-10.
Sep 22, 2022Swiss Recommendations for Cutaneous Basal Cell Carcinoma.
Sep 22, 2022Dermatology 2022; 239:1-10
Ramelyte Egle, Nägeli Mirjam, Hunger Robert, Merat Rastine, Gaide Olivier, Navarini Alexander A, Cozzio Antonio, Wagner Nikolaus, Maul Lara Valeska, Dummer Reinhard
Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.
Gaissler A, Meldgaard T, Heeke C, Babaei S, Tvingsholm S, Bochem J, Spreuer J, Amaral T, Wagner N, Klein R, Meier F, Garbe C, Eigentler T, Pawelec G, Claassen M, Weide B, Hadrup S, Wistuba-Hamprecht K. Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade. Front Immunol 2022; 13:906352.
Jul 7, 2022Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.
Jul 7, 2022Front Immunol 2022; 13:906352
Gaissler Andrea, Meldgaard Trine Sundebo, Heeke Christina, Babaei Sepideh, Tvingsholm Siri Amanda, Bochem Jonas, Spreuer Janine, Amaral Teresa, Wagner Nikolaus, Klein Reinhild, Meier Friedegund, Garbe Claus, Eigentler Thomas K, Pawelec Graham, Claassen Manfred, Weide Benjamin, Hadrup Sine Reker, Wistuba-Hamprecht Kilian
Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown.
Kostner L, Cerminara S, Pamplona G, Maul J, Dummer R, Ramelyte E, Mangana J, Wagner N, Cozzio A, Kreiter S, Kogler A, Streit M, Wysocki A, Zippelius A, Läubli H, Navarini A, Maul L. Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown. Cancers (Basel) 2022; 14
May 10, 2022Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown.
May 10, 2022Cancers (Basel) 2022; 14
Kostner Lisa, Cerminara Sara Elisa, Pamplona Gustavo Santo Pedro, Maul Julia-Tatjana, Dummer Reinhard, Ramelyte Egle, Mangana Johanna, Wagner Nikolaus, Cozzio Antonio, Kreiter Saskia, Kogler Angelika, Streit Markus, Wysocki Anja, Zippelius Alfred, Läubli Heinz, Navarini Alexander, Maul Lara Valeska
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Purde M, Niederer R, Wagner N, Diem S, Berner F, Hasan Ali O, Hillmann D, Bergamin I, Jörger M, Risch M, Niederhauser C, Lenz T, Früh M, Risch L, Semela D, Flatz L. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. J Cancer Res Clin Oncol 2021; 148:647-656.
Dec 7, 2021Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Dec 7, 2021J Cancer Res Clin Oncol 2021; 148:647-656
Purde Mette-Triin, Niederer Rebekka, Wagner Nikolaus, Diem Stefan, Berner Fiamma, Hasan Ali Omar, Hillmann Dorothea, Bergamin Irina, Jörger Markus, Risch Martin, Niederhauser Christoph, Lenz Tobias L, Früh Martin, Risch Lorenz, Semela David, Flatz Lukas
Histological and Immunohistochemical Changes of Congenital Melanocytic Nevi With Age
Gassenmaier M, Häfner H, Hahn M, Kofler L, Wagner N, Forchhammer S. Histological and Immunohistochemical Changes of Congenital Melanocytic Nevi With Age. Am J Dermatopathol 2021; 43:707-713.
Oct 1, 2021Histological and Immunohistochemical Changes of Congenital Melanocytic Nevi With Age
Oct 1, 2021Am J Dermatopathol 2021; 43:707-713
Gassenmaier Maximilian, Häfner Hans-Martin, Hahn Matthias, Kofler Lukas, Wagner Nikolaus, Forchhammer Stephan
Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas
Gassenmaier M, Hahn M, Metzler G, Bauer J, Yazdi A, Keim U, Garbe C, Wagner N, Forchhammer S. Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas. Cancers (Basel) 2021; 13
Jul 31, 2021Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas
Jul 31, 2021Cancers (Basel) 2021; 13
Gassenmaier Maximilian, Hahn Matthias, Metzler Gisela, Bauer Jürgen, Yazdi Amir Sadegh, Keim Ulrike, Garbe Claus, Wagner Nikolaus, Forchhammer Stephan
Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
Gassenmaier M, Lenders M, Forschner A, Leiter U, Weide B, Garbe C, Eigentler T, Wagner N. Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors. Target Oncol 2021; 16:197-205.
Feb 8, 2021Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
Feb 8, 2021Target Oncol 2021; 16:197-205
Gassenmaier Maximilian, Lenders Max M, Forschner Andrea, Leiter Ulrike, Weide Benjamin, Garbe Claus, Eigentler Thomas K, Wagner Nikolaus
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
Wagner N, Schraag A, Klumpp B, Hoetzenecker W, Berking C, Richtig E, Ziemer M, Mangana J, Terheyden P, Loquai C, Nguyen V, Gebhardt C, Meier F, Diem S, Cozzio A, Flatz L, Röcken M, Garbe C, Gassenmaier M, Weide B, Leiter U, Lenders M, Kühl K, Reinhardt L, André F, Dudda M, Ring N, Ebel C, Stäger R, Zellweger C, Lang R, Paar M, Gussek P, Richtig G, Stürmer S, Kimeswenger S, Oellinger A, Forschner A, Eigentler T. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. J Immunother Cancer 2021; 9
Jan 1, 2021Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
Jan 1, 2021J Immunother Cancer 2021; 9
Wagner Nikolaus, Schraag Amadeus, Klumpp Bernhard, Hoetzenecker Wolfram, Berking Carola, Richtig Erika, Ziemer Mirjana, Mangana Johanna, Terheyden Patrick, Loquai Carmen, Nguyen Van Anh, Gebhardt Christoffer, Meier Friedegund, Diem Stefan, Cozzio Antonio, Flatz Lukas, Röcken Martin, Garbe Claus, Gassenmaier Maximilian, Weide Benjamin, Leiter Ulrike, Lenders Max M, Kühl Kathrin, Reinhardt Lydia, André Fiona, Dudda Milena, Ring Natalie, Ebel Chiara, Stäger Ramon, Zellweger Caroline, Lang Roland, Paar Michael, Gussek Philipp, Richtig Georg, Stürmer Suzan H, Kimeswenger Susanne, Oellinger Angela, Forschner Andrea, Eigentler Thomas K
Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors
Winter J, Eigentler T, Garbe C, Röcken M, Cozzio A, Flatz L, Purde M, Weide B, Leiter U, Forschner A, Gassenmaier M, Lenders M, Wagner N. Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. Cancer Immunol Immunother 2020; 70:1089-1099.
Oct 28, 2020Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors
Oct 28, 2020Cancer Immunol Immunother 2020; 70:1089-1099
Winter Johanna, Eigentler Thomas K, Garbe Claus, Röcken Martin, Cozzio Antonio, Flatz Lukas, Purde Mette-Triin, Weide Benjamin, Leiter Ulrike, Forschner Andrea, Gassenmaier Maximilian, Lenders Max M, Wagner Nikolaus
Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors
Gassenmaier M, Garbe C, Schaller M, Wagner N, Bösmüller H, Niessner H, Sinnberg T, Kosnopfel C, Ikenberg K, Eigentler T, Fehrenbacher B, Rentschler M, Röcken M. Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors. Am J Pathol 2020; 190:2155-2164.
Jul 15, 2020Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors
Jul 15, 2020Am J Pathol 2020; 190:2155-2164
Gassenmaier Maximilian, Garbe Claus, Schaller Martin, Wagner Nikolaus, Bösmüller Hans, Niessner Heike, Sinnberg Tobias, Kosnopfel Corinna, Ikenberg Kristian, Eigentler Thomas K, Fehrenbacher Birgit, Rentschler Maximilian, Röcken Martin
Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy
Wagner N, Luttermann F, Gassenmaier M, Forschner A, Leiter U, Garbe C, Eigentler T. Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy. Australas J Dermatol 2020; 61:e310-e318.
Feb 12, 2020Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy
Feb 12, 2020Australas J Dermatol 2020; 61:e310-e318
Wagner Nikolaus, Luttermann Felix, Gassenmaier Maximilian, Forschner Andrea, Leiter Ulrike, Garbe Claus, Eigentler Thomas K
Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
Wagner N, Utikal J, Umansky V, Garbe C, Schadendorf D, Holland-Letz T, Herpel E, Sucker A, Lichtenberger R, Funder A, Kehrel C, Kemper C, Schuermans V, Tarnanidis K, Reith M, Gries M, Weide B, Gebhardt C. Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. J Immunother Cancer 2019; 7:343.
Dec 5, 2019Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
Dec 5, 2019J Immunother Cancer 2019; 7:343
Wagner Nikolaus, Utikal Jochen, Umansky Viktor, Garbe Claus, Schadendorf Dirk, Holland-Letz Tim, Herpel Esther, Sucker Antje, Lichtenberger Ramtin, Funder Anne, Kehrel Coretta, Kemper Charlotte, Schuermans Valerie, Tarnanidis Kathrin, Reith Maike, Gries Mirko, Weide Benjamin, Gebhardt Christoffer
Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
Bochem J, Weide B, Pawelec G, Garbe C, Meier F, Terheyden P, Uslu U, Wagner N, Eigentler T, Soffel D, Spreuer J, Amaral T, Zelba H, Wistuba-Hamprecht K. Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. PloS one 2019; 14:e0221301.
Aug 16, 2019Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
Aug 16, 2019PloS one 2019; 14:e0221301
Bochem Jonas, Weide Benjamin, Pawelec Graham, Garbe Claus, Meier Friedegund, Terheyden Patrick, Uslu Ugur, Wagner Nikolaus, Eigentler Thomas, Soffel Daniel, Spreuer Janine, Amaral Teresa, Zelba Henning, Wistuba-Hamprecht Kilian
S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
Wagner N, Forschner A, Leiter U, Garbe C, Eigentler T. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. Br J Cancer 2018; 119:339-346.
Jun 28, 2018S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
Jun 28, 2018Br J Cancer 2018; 119:339-346
Wagner Nikolaus, Forschner Andrea, Leiter Ulrike, Garbe Claus, Eigentler Thomas K
Safety of shortened infusion times for combined ipilimumab and nivolumab
Gassenmaier M, Garbe C, Eigentler T, Doecker D, Mueller A, Kofler L, Wagner N, Scheu A, Lipp H, Forschner A. Safety of shortened infusion times for combined ipilimumab and nivolumab. Cancer Immunol Immunother 2017; 67:135-140.
Oct 7, 2017Safety of shortened infusion times for combined ipilimumab and nivolumab
Oct 7, 2017Cancer Immunol Immunother 2017; 67:135-140
Gassenmaier Maximilian, Garbe Claus, Eigentler Thomas Kurt, Doecker Dennis, Mueller Alisa, Kofler Lukas, Wagner Nikolaus, Scheu Alexander, Lipp Hans-Peter, Forschner Andrea
Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma
Wagner N, Utikal J, Enk A, Umansky V, Garbe C, Naeher H, Holland-Letz T, Busch C, Ikenberg K, Eubel J, Herpel E, Pflugfelder A, Lichtenberger R, Kehrel C, Tarnanidis K, Reith M, Weide B, Gebhardt C. Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. Int J Cancer 2015; 137:2607-17.
Jul 14, 2015Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma
Jul 14, 2015Int J Cancer 2015; 137:2607-17
Wagner Nikolaus, Utikal Jochen, Enk Alexander, Umansky Viktor, Garbe Claus, Naeher Helmut, Holland-Letz Tim, Busch Christian, Ikenberg Kristian, Eubel Jana, Herpel Esther, Pflugfelder Annette, Lichtenberger Ramtin, Kehrel Coretta, Tarnanidis Kathrin, Reith Maike, Weide Benjamin, Gebhardt Christoffer